Pays: Australie
Langue: anglais
Source: Department of Health (Therapeutic Goods Administration)
relugolix, Quantity: 40 mg; estradiol, Quantity: 1 mg (Equivalent: estradiol hemihydrate, Qty 1.032 mg); norethisterone acetate, Quantity: 0.5 mg
Gedeon Richter Australia Pty Ltd
Tablet, film coated
Excipient Ingredients: mannitol; sodium starch glycollate type A; magnesium stearate; lactose monohydrate; hyprolose; titanium dioxide; hypromellose; triacetin; iron oxide yellow
Oral
28 tablets, 3 x 28 tablets (84 tablets total)
(S4) Prescription Only Medicine
Ryeqo is indicated in adult women of reproductive age for:,? treatment of moderate to severe symptoms of uterine fibroids,,?symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis (see section 5.1 PHARMACODYNAMIC PROPERTIES).
Visual Identification: Round, light yellow to yellow, film-coated tablet, debossed on one side with "415".; Container Type: Bottle; Container Material: HDPE; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure
Registered
2022-09-06
RYEQO 1 RYEQO® CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side effects. See the full CMI for further details. [Include if applicable] 1. WHY AM I USING RYEQO? RYEQO contains the active ingredients relugolix, estradiol hemihydrate and norethisterone acetate. RYEQO® is used to treat moderate to severe symptoms of uterine fibroids (commonly known as myomas). For more information, see Section 1. Why am I using RYEQO? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE RYEQO? Do not use if you have ever had an allergic reaction to RYEQO or any of the ingredients listed at the end of the CMI. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. For more information, see Section 2. What should I know before I use RYEQO? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with RYEQO and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE RYEQO? • Take one tablet each day. • The tablet must be taken orally every day, at about the same time, with or without food with a little liquid. More instructions can be found in Section 4. How do I use RYEQO? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING RYEQO? THINGS YOU SHOULD DO • Remind any doctor, dentist or pharmacist you visit that you are using RYEQO. • Tell your doctor if you have any medical conditions, take any medicines for any other condition, or are planning on having surgery. • Tell your doctor if you become pregnant whilst using RYEQO. THINGS YOU SHOULD NOT DO • Do not stop using RYEQO before talking to your doctor first. DRIVING OR USING MACHINES • Be careful before you drive or use any machines or tools until you know how RYEQO affects you. • Lire le document complet
Product and Consumer Medicine Information Licence ------------------------- ACCESS TERMS FOR PRODUCT INFORMATION AND CONSUMER MEDICINE INFORMATION DOCUMENTS ("LICENCE") PARTIES YOU or YOUR means any legal person or entity who accesses or downloads a PI Document or CMI Document from Our website and US, WE or OUR means the COMMONWEALTH OF AUSTRALIA as represented by the THERAPEUTIC GOODS ADMINISTRATION ABN 40 939 406 804 of 136 Narrabundah Lane, Symonston ACT 2609, Australia. OPERATIVE PROVISIONS * NATURE OF AGREEMENT * 1.1 This Licence specifies the terms and conditions of Your access and use of PI Documents and CMI Documents made available to the general public by Us via Our website. * 1.2 You acknowledge and agree that accessing PI Documents or CMI Documents in accordance with this Licence is beneficial to You because it provides You with product information about therapeutic goods and is beneficial to Us because it assists Us in our portfolio responsibilities. * TERMS OF ACCESS * 2.1 We grant to You a perpetual, non-exclusive, royalty-free, world-wide, irrevocable and non-transferable licence to download, store in cache, display, print and copy a single copy or part of a single copy of a PI Document or CMI Document made available via Our website. * 2.2 If You wish to use any PI Document or CMI Document for purposes other than those specified in clause 2.1 of this Licence, You must seek the permission of the Sponsor. * 2.3 We may remove a PI Document or CMI Document from Our website at any time in Our sole discretion. * EXCLUSION OF LIABILITY * 3.1 You acknowledge and agree that You are responsible for making Your own enquiries to determine whether any PI Document or CMI Document is accurate, up to date and fit for Your purposes. * 3.2 The PI Document or CMI Document is provided to You for the purpose of disseminating health information free of charge for the benefit of the public. This Licence and any PI Document or CMI Document made available to You via Our website is not a substitute fo Lire le document complet